Philippe Gabriel Steg

Learn More
AIMS Natural history and prognosis of acute coronary syndrome (ACS) in HIV-infected patients remain to be determined. We sought to compare coronary risk factors, angiographic features, acute results of percutaneous coronary intervention, in-hospital outcomes, and pre-specified 1 year prognosis of HIV-infected and HIV-uninfected patients with ACS. METHODS(More)
OBJECTIVES Risk scores are recommended in guidelines to facilitate the management of patients who present with acute coronary syndromes (ACS). Internationally, such scores are not systematically used because they are not easy to apply and some risk indicators are not available at first presentation. We aimed to derive and externally validate a more accurate(More)
Oxygen supplementation is a standard treatment for all patients who present with acute coronary syndrome, regardless of oxygen saturation levels. Most of the data regarding the function of oxygen in myocardial infarction is based on a limited number of basic and clinical studies. We performed a systematic literature review that explores the basic and(More)
AIMS To explore the variations in the use of invasive coronary procedures after acute coronary syndromes. METHODS AND RESULTS In the ENACT registry, use of invasive procedures was analyzed as a function of hospital type, country and patient characteristics among 2768 patients with acute coronary syndromes (731 with ST-segment elevation myocardial(More)
BACKGROUND Atherothrombosis, a generalized and progressive process, is currently a major healthcare problem in Mexico. METHODS The worldwide Reduction of Atherothrombosis for Continued Health (REACH) registry aimed to evaluate risk factors for atherosclerosis, long-term cardiovascular (CV) event rates, and current management of either patients with(More)
BACKGROUND Continued dual antiplatelet therapy and optimal medical therapy (OMT) improve outcomes in selected patient populations with established coronary heart disease, but whether OMT modifies the treatment effect of dual antiplatelet therapy is unknown. METHODS The DAPT (Dual Antiplatelet Therapy) Study, a double-blind trial, randomly assigned 11 648(More)
OBJECTIVE The effects of ticagrelor in the subpopulation of patients with ST-elevation myocardial infarction (STEMI) were consistent with those observed in the overall Platelet Inhibition and Patient Outcomes (PLATO) study. However, this subgroup included patients initially or ultimately treated conservatively. The aim of this study is to compare treatment(More)
BACKGROUND To use CLARIFY, a prospective registry of patients with stable CAD (45 countries), to explore heart rate (HR) control and beta-blocker use. METHODS We analyzed the CLARIFY population according to beta-blocker use via descriptive statistics with Pearson's χ(2) test for comparisons, as well as a multivariable stepwise model. RESULTS Data on(More)
PURPOSE Aspirin, a potent platelet inhibitor, is widely used in patients with cardiovascular diseases. Platelet aggregation is the cornerstone of acute atherothrombotic complications. ACTUALITIES Aspirin showed significant benefits when administered in patients with acute myocardial infarction or unstable angina, and also when used for secondary(More)